ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)
$5.2 -0.12 (-2.2556%)
Analysed ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) News Sources
Companies Like Aclaris Therapeutics (NASDAQ:ACRS) Are In A Position To Invest In Growth
04-05-2026
yahoo.com
Rigel Pharmaceuticals (RIGL) Lags Q1 Earnings and Revenue Estimates
05-05-2026
yahoo.com
Aclaris Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate and Clinical Update
07-05-2026
yahoo.com
Aclaris Therapeutics (ACRS) Reports Q1 Loss, Beats Revenue Estimates
07-05-2026
yahoo.com
Aclaris Therapeutics to Participate in the 2026 Bank of America Healthcare Conference
08-05-2026
yahoo.com
Aclaris Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
28-05-2026
yahoo.com
Aclaris Therapeutics Maps Busy Pipeline Calendar, Plans Phase 2 Asthma Trial for ATI-052
04-06-2026
marketbeat.com
Aclaris Therapeutics, Inc. (ACRS): A Top Penny Stock in Investors Portfolio That Stifel is Bullish On
07-06-2026
yahoo.com
3 Penny Stocks Under $5 Backed by Real Revenue Growth
20-06-2026
marketbeat.com
Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength?
01-07-2026
yahoo.com
What is the current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The current price of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is $5.2.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) absolute price change since previous trading day?
The absolute price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is $-0.12.
ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) percentage price change since previous trading day?
The percentage price change of ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) since the previous trading day is -2.2556%.
What is the most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent average sentiment score for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is 70 out of 100.
What is the most recent average sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)?
The most recent sentiment for ACLARIS THERAPEUTICS INC (ACRS:NASDAQ) is .
SEC-8K** Filing Available For ACLARIS THERAPEUTICS INC (ACRS:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.